Ignite Creation Date:
2024-05-05 @ 10:00 PM
Last Modification Date:
2024-10-26 @ 10:12 AM
Study NCT ID:
NCT01004081
Status:
COMPLETED
Last Update Posted:
2015-10-02
First Post:
2009-09-18
Brief Title:
Hormone Receptor Positive Metastatic Breast Cancer HR mBC BIIB021 Plus Aromasin Schedule Finding
Sponsor:
Biogen
Organization:
Biogen
Study Overview
Official Title:
Phase 2a Open-Label Randomized Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status:
COMPLETED
Status Verified Date:
2011-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the efficacy safety and tolerability of 2 dosing regimens of BIIB021 in combination with exemestane in women whose HR breast cancer had progressed following treatment with a nonsteroidal aromatase inhibitor AI
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None